Advertisement
Document › Details
Pieris Pharmaceuticals, Inc.. (3/6/18). "Press Release: Pieris Pharmaceuticals to Present at Investor Conferences in March". Boston, MA.
Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for cancer, respiratory and other diseases, announced today that Pieris will present at the following upcoming investor conferences:
> The Cowen & Company 38th Annual Health Care Conference, Tuesday, March 13, 2018 at 8:40 a.m. EDT at the Marriott Copley Place in Boston. A webcast of the presentation can be accessed by visiting this link.
> The Oppenheimer & Co. 28th Annual Healthcare Conference, Tuesday, March 20, 2018 at 11:30 a.m. EDT at the Westin New York Grand Central in New York City. A webcast of the presentation can be accessed by visiting this link.
About Pieris Pharmaceuticals
Pieris is a clinical-stage biotechnology company that discovers and develops Anticalin protein-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes immuno-oncology multi-specifics tailored for the tumor microenvironment, an inhaled Anticalin protein to treat uncontrolled asthma and a half-life-optimized Anticalin protein to treat anemia. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Anticalin® is a registered trademark of Pieris. For more information, visit www.pieris.com.
Forward Looking Statements
This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to novel technologies and methods; our business and product development plans; the timing and progress of our studies, including the timing of enrollment and dosing of PRS-343 patients and PRS-060 healthy subjects; the enrollment of patients in the PRS-080 multi-dose trial and dosing healthy subjects; our liquidity and ability to fund our future operations; our ability to achieve certain milestones and receive future milestone or royalty payments; or market information. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, our ability to raise the additional funding we will need to continue to pursue our business and product development plans; the inherent uncertainties associated with developing new products or technologies and operating as a development stage company; our ability to develop, complete clinical trials for, obtain approvals for and commercialize any of our product candidates, including our ability to recruit and enroll patients in our studies; our ability to address the requests of the FDA; competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this press release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents we file with the SEC available at www.sec.gov, including without limitation the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2016 and the Company's Quarterly Reports on Form 10-Q.
Company Contact:
Allan Reine
SVP & Chief Financial Officer
+1-857-444-4276
reine@pieris.com
Investor Relations Contact:
The Trout Group
Thomas Hoffmann
+1-646-378-2931
thoffmann@troutgroup.com
Media Inquiries:
Trophic Communications
Gretchen Schweitzer
+49 89 238 87730
schweitzer@trophic.eu
Record changed: 2023-06-05 |
Advertisement
More documents for Pieris (Group)
- [1] Pieris Pharmaceuticals, Inc.. (8/17/23). "Press Release: Pieris Pharmaceuticals Announces Milestone Achievement for Boston Pharmaceuticals' Initiation of Phase 1/2 Study of BOS-342, a 4-1BB/GPC3 Immuno-Oncology Bispecific". Boston, MA....
- [2] Pieris Pharmaceuticals, Inc.. (7/18/23). "Press Release: Pieris Pharmaceuticals Provides Strategic Update and Announces Restructuring". Boston, MA....
- [3] Pieris Pharmaceuticals, Inc.. (6/21/23). "Press Release: Pieris Pharmaceuticals Announces AstraZeneca Discontinuation of Phase 2a Trial of Elarekibep (PRS-060/AZD1402) Due to New Non-Clinical Safety Findings From 13-week Toxicology Study". Boston, MA....
- [4] Pieris Pharmaceuticals, Inc.. (4/17/23). "Press Release: Pieris Pharmaceuticals Announces Presentation of Positive Clinical Data for Cinrebafusp Alpa (PRS-343) At 2023 AACR Annual Meeting". Boston, MA....
- [5] MorphoSys AG. (8/31/22). "Press Release: MorphoSys Appoints Tim Demuth as New Chief Research and Development Officer, Following the Retirement of Malte Peters". Planegg....
- [6] Pieris Pharmaceuticals, Inc.. (10/6/21). "Press Release: Pieris Pharmaceuticals Announces Appointments of Chief Financial Officer and Chief Business Officer". Boston, MA....
- [7] Pieris Pharmaceuticals, Inc.. (11/4/19). "Press Release: Pieris Pharmaceuticals Announces $32 Million Private Placement and Potential Funding Mechanism for PRS-060 Co-development Opt-in". Boston, MA....
- [8] Pieris Pharmaceuticals, Inc.. (8/1/19). "Press Release: Pieris Pharmaceuticals Appoints Dr. Maya Said to its Board of Directors". Boston, MA....
- [9] Pieris Pharmaceuticals, Inc.. (8/1/19). "Press Release: Pieris Pharmaceuticals Reports Second Quarter 2019 Cash Position and Provides Corporate Update". Boston, MA....
- [10] Pieris Pharmaceuticals, Inc.. (9/10/18). "Press Release: Pieris Pharmaceuticals Appoints Peter Kiener, D.Phil., to its Board of Directors". Boston, MA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Advertisement
» top